Lacerta Therapeutics, a Gainesville, FL-based clinical-stage gene therapy company, closed a $30m funding round.
Lacerta is a resident of UF Innovate | Sid Martin Biotech, a biotechnology incubator at the University of Florida.
Sarepta Therapeutics (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine, has made the equity investment gaining rights to multiple CNS-targeted gene therapy programs.
The company will use the new funding to advance its clinical pipeline.
Led by Joseph Reddy, Ph.D., President and Chief Executive Officer, and Kenneth Warrington, Ph.D., Chief Technology Officer, Lacerta Therapeutics is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases.